Articles
23.06.2020
COVID-19 impact on pricing and market access

Without a doubt, the impact of COVID-19 will influence all sectors, including the future of market a...

Read more
Articles
11.06.2020
What is real-world evidence

Real-world evidence refers to clinical and economic evidence which has been derived from the analysi...

Read more
Articles
02.06.2020
Artificial intelligence in market access

AI technologies are becoming increasingly relevant in many fields, such as business and marketing an...

Read more
Articles
28.05.2020
Scottish Medicines Consortium (SMC)

NICE has announced they will begin a phased restart of publishing guidance, whilst SMC meetings are ...

Read more
Articles
20.05.2020
International Reference Pricing

IRP is a pricing mechanism where the price of a drug in one country is set or adjusted in relation t...

Read more
Articles
12.05.2020
Price and market access price affected by COVID

We received fabulous feedback, with responses from at least 15 industry executives across global pha...

Read more
Articles
05.05.2020
Remote delivery of market access training

Whilst many businesses are currently working remotely, up-skilling your workforce through interactiv...

Read more
Articles
30.04.2020
EU P&MA implications for developments

CAR T-cell therapies and speculation in the pricing and market access implications for the lymphoma ...

Read more
Articles
24.04.2020
What are Managed Entry Agreements

Arrangements made between manufacturers and payers which are being implemented for innovative treatm...

Read more
Articles
31.03.2020
The impact of Covid-19 on payer and HTA decisions

Given the shutdown occurring in response to COVID-19, payers and HTA bodies are struggling to adjust...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.